Homologous Recombination Deficiency (HRD) testing in ovarian cancer [Tissue]
HRD testing for Ovarian Cancer (Tissue). This EQA is sponsored.
Sponsored by
Overview
The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.
At a glance
Product Code:
02-HRD-27
Target/Genes:
This EQA is designed for laboratories to test the Homologous Recombination Deficiency (HRD) status, including determining the genomic instability status and to identify variants in Homologous Recombination Repair (HRR) genes in the context of PARP inhibitor therapy for ovarian cancer patients.
Technology:
CNV, NGS, Panel testing
Sample Type:
FFPE
Submit Results In:
English, French, German, Italian, Spanish
Accredited:
Pending
Key Dates
28/02/2027
Sep-27
Sept - Nov 2027
May - June 2028
Sample Details
Three mock clinical cases with matching samples will be provided.
Two 10µm FFPE sections per case are provided.
Samples are provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.
EQA Results
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participation Information
Participants are expected to test the samples according to their routine strategy. For all cases, participants are expected to return a clinical report and complete an online data collection form.
This EQA is supported by an educational grant from AstraZeneca and MSD, fees are subsidised so there is a reduced cost for participants. EMQN acknowledge and thank AstraZeneca and MSD for this support.
Limited to 110 participants, please register early to avoid disappointment. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
Send your enquiry by submitting the form
Closes in 111 days
From £310.00
Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.
- Submit results in 5 languages
Questions about this scheme?
Contact our team
Register Interest
Express your interest in ''.